Cefuroxime: Nursing Drug Guide, CDAD Risk & Allergy Screening
Second-generation cephalosporin for oral (axetil), IV, and IM routes: verify beta-lactam allergy history before every dose, watch for watery or bloody diarrhea that may signal C. difficile—even months after therapy—and adjust renal dosing intervals when creatinine clearance falls below 30 mL/min (oral) or per IV renal tables.
Clostridioides difficile-associated diarrhea (CDAD) has been reported with cefuroxime axetil and IV cefuroxime and may range from mild diarrhea to fatal colitis—including symptoms that begin during therapy or more than two months after the last dose. If CDAD is suspected, ongoing antibacterial therapy not directed against C. difficile may need to be discontinued per prescriber guidance. Before the first dose, inquire about hypersensitivity to penicillins, cephalosporins, and other beta-lactams; individuals with penicillin allergy have experienced severe reactions with cephalosporins. Cefuroxime is contraindicated in known beta-lactam hypersensitivity. Unadjusted renal dosing can prolong drug exposure and has been associated with seizures with cephalosporins—verify interval adjustment when creatinine clearance is reduced.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose, confirm beta-lactam allergy history, teach that watery or bloody diarrhea can signal C. difficile even weeks after therapy ends, and never substitute oral tablet and suspension doses mg-for-mg—they are not bioequivalent. Extend dosing intervals when creatinine clearance is below 30 mL/min (oral axetil) or per IV renal tables; seizures have occurred when cephalosporin doses were not reduced in renal impairment.
Most common brand names
Cefuroxime is available as the prodrug cefuroxime axetil for oral tablets and suspension and as cefuroxime sodium for IV and IM use. Common U.S. brands include Ceftin (oral axetil) and Zinacef (IV/IM). Generic products are widely used—always match the ordered salt, formulation, and strength on the MAR.
Do not confuse cefuroxime with other beta-lactams: cephalexin (first-generation cephalosporin), ceftriaxone (third-generation), or amoxicillin (penicillin) when verifying allergies and duplicate antibiotic orders.
Why we give it — Indications
Cefuroxime treats infections caused by susceptible organisms when culture, susceptibility, or local epidemiology supports its use. Labeling stresses using cefuroxime only for proven or strongly suspected bacterial infections to limit resistance. Nurses commonly see orders for respiratory, skin, urinary, and selected systemic infections.
| Use (labeled examples) | Typical adult oral dose (axetil) | Duration |
|---|---|---|
| Acute sinusitis / pharyngitis | 250 mg every 12 hours | 10 days |
| Acute bacterial exacerbation of bronchitis | 250–500 mg every 12 hours | Per prescriber (often 5–10 days) |
| Uncomplicated skin / soft-tissue infection (cellulitis context) | 250–500 mg every 12 hours | Per prescriber |
| Uncomplicated urinary tract infection | 250 mg every 12 hours | 7–10 days |
| Early Lyme disease | 500 mg every 12 hours | 20 days |
| Uncomplicated gonorrhea | 1000 mg single oral dose | Single dose |
| Inpatient pneumonia / severe infection (IV sodium) | 750 mg–1.5 g IV every 8 hours | Per prescriber and culture data |
On a small screen, swipe or scroll sideways to see the full table.
Confirm the ordered formulation matches the infection site and severity—oral axetil for many outpatient regimens, IV or IM sodium when parenteral therapy is required.
How it works
Cefuroxime is a second-generation cephalosporin. Bactericidal activity results from inhibition of bacterial cell-wall synthesis. Oral cefuroxime axetil is a prodrug converted to active cefuroxime after absorption. Renal excretion is the predominant elimination pathway; activity is primarily due to parent drug with limited metabolism per prescribing information.
Dosing overview
Oral tablets are supplied as 250 mg and 500 mg cefuroxime axetil. IV/IM cefuroxime sodium is typically dosed in grams per day divided every 6–8 hours. Verify formulation, salt, renal function, and whether the patient is receiving oral or parenteral therapy before administration.
Oral axetil — renal dose adjustment
| Creatinine clearance | Dosing interval |
|---|---|
| ≥ 30 mL/min | No adjustment to standard dose |
| 10 to < 30 mL/min | Standard daily dose every 24 hours |
| < 10 mL/min | Standard daily dose every 48 hours |
| Hemodialysis | Extra dose at end of each dialysis session per labeling |
On a small screen, swipe or scroll sideways to see the full table.
IV sodium — renal dose adjustment
| Creatinine clearance | 750 mg dose interval |
|---|---|
| > 20 mL/min | Every 8 hours (usual) |
| 10–20 mL/min | Every 12 hours |
| < 10 mL/min | Every 24 hours |
| Hemodialysis | Dose after dialysis per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact pharmacy or prescriber for guidance, especially near the end of a fixed-duration course or when renal function has changed.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Peak (oral axetil) | Approximately 2–3 hours after dose | Symptom improvement may lag behind peak levels; reassess clinical response over 48–72 hours |
| Food | May take with or without food | Absorption is reduced by antacids, H₂ blockers, and PPIs—plan timing separately |
| Elimination | Principally renal | Prolonged exposure when CrCl is reduced—extend dosing interval per tables above |
| Duration of therapy | Indication-specific (e.g., 10 days sinusitis; 20 days Lyme) | Document completion unless prescriber discontinues early for toxicity or culture data |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Allergy history: cephalosporins, penicillins, carbapenems, and prior beta-lactam reactions; cross-hypersensitivity among beta-lactams may occur
- Current and recent antibiotics—duplicate beta-lactam therapy increases resistance and CDAD risk; perform medication reconciliation
- Renal function (serum creatinine, estimated CrCl or eGFR)—adjust oral or IV interval when clearance is reduced
- Scheduled antacids, H₂-receptor antagonists, or proton-pump inhibitors—plan separation; PPIs and H₂ blockers reduce oral absorption per labeling
- Baseline stool pattern and GI symptoms before starting therapy
Contraindications
- Known hypersensitivity to cefuroxime, any cephalosporin, or other beta-lactam antibacterial
Important interactions
| Drug / substance | Effect | Nursing action |
|---|---|---|
| Antacids (aluminum or magnesium) | Reduced oral absorption | Give cefuroxime axetil at least 1 hour before or 2 hours after antacids per labeling |
| H₂ blockers / proton-pump inhibitors | Reduced oral absorption | Avoid concurrent PPI or H₂ therapy when possible; coordinate with pharmacy for oral regimens |
| Probenecid | Not recommended—may alter renal excretion | Notify pharmacist if probenecid is ordered; verify cefuroxime plan before administration |
| Urinalysis interference | False-positive urine glucose with copper reduction tests (Clinitest, Benedict, Fehling) | Use enzyme-based glucose test strips per labeling; document antibiotic on lab requisition |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral axetil: Tablets (250 mg, 500 mg) or reconstituted suspension. Swallow tablets whole—crushing produces a bitter taste and is not recommended per labeling. May be given with or without food.
IV/IM sodium: Administer by direct IV push over 3–5 minutes or as an infusion per institutional protocol. Follow IV medication administration rights, compatibility checks, and line patency standards.
- Do not substitute oral tablet and suspension doses mg-for-mg—verify pharmacy label strength and volume
- Separate antacids by at least 1 hour before or 2 hours after oral axetil; coordinate PPI/H₂ timing with pharmacy
- Shake suspension well before each dose; use an oral syringe or calibrated device
- Complete the full prescribed course unless toxicity or prescriber discontinuation; stopping early promotes resistance
- Document dose, route, time, and patient tolerance on the MAR
Expected therapeutic response
- Decreasing fever and improving infection-related symptoms over 48–72 hours when the organism is susceptible
- Stable or improving vital signs without new hypotension, tachycardia, or respiratory deterioration
- Absence of new watery or bloody diarrhea, abdominal distention, or toxicity signs suggesting CDAD
- Culture or clinical follow-up per prescriber when symptoms do not improve within the expected timeframe
Red flags — Stop and act
Stop the dose, notify the prescriber, and escalate urgently when any of the following occur:
- Watery or bloody stools, abdominal cramping, or diarrhea with fever during or after therapy—consider antibiotic-associated diarrhea and CDAD even months later
- Rash, hives, facial or laryngeal swelling, wheezing, or signs of anaphylaxis
- Seizure activity—cephalosporins have triggered seizures when dosage was not reduced in renal impairment per labeling
- New jaundice, dark urine, or severe GI bleeding
- Signs of cerebral irritation after overdose or accumulation (confusion, convulsions)
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Diarrhea | ~4% in clinical trials | Differentiate mild loose stools from CDAD; obtain stool studies and contact prescriber if watery or bloody |
| Nausea / vomiting | ~3% in clinical trials | Supportive care; hold and notify if persistent vomiting or signs of colitis |
| Rash | Reported in trials and postmarketing | Stop cefuroxime at first significant rash; escalate for mucosal involvement or systemic symptoms |
| CDAD / pseudomembranous colitis | Serious; may be fatal | Hold antibiotic, isolation precautions per facility, notify prescriber and infection prevention |
| Anaphylaxis, serum sickness-like reactions | Rare; fatalities reported | Stop drug permanently; emergency response per protocol |
| Seizures (renal overdose context) | Reported with cephalosporins when doses not adjusted | Verify renal interval; discontinue and treat per seizure protocol |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdose may cause cerebral irritation and convulsions. With other beta-lactams, nausea, vomiting, epigastric distress, and diarrhea have also occurred.
Antidote / removal
No specific antidote is listed. Hemodialysis and peritoneal dialysis remove cefuroxime from the body and may be useful after serious toxic reactions, particularly when renal function is compromised. Contact local poison control or medical toxicology services per facility protocol and local emergency guidance.
Several cephalosporins have triggered seizures when dosage intervals were not extended in renal impairment. If seizures occur during therapy, discontinue the drug and treat per seizure protocol.
Look-alike / sound-alike and error prevention
- Cefuroxime vs cephalexin vs ceftriaxone—verify generic name on MAR; generation, spectrum, and dosing differ
- Ceftin (oral) vs Zinacef (IV/IM)—confirm salt, route, and strength before administration
- Tablet vs suspension—not mg-for-mg substitutable; verify pharmacy label
- Oral vs IV renal tables—different interval rules; pharmacy should verify CrCl and route together
- Crush error—tablets are bitter if crushed; use appropriate formulation for swallowing difficulty
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Antacid / PPI timing | Chart separation from oral axetil—many “given” doses are not fully absorbed when taken with stomach medicines |
| IV push | 3–5 minute direct IV injection or infusion per protocol—do not bolus faster than labeling allows |
| Renal sticker | When CrCl drops mid-course, flag pharmacy before the next IV q8h dose |
| Lab interference | Warn patients using copper-reduction urine glucose tests; prefer enzyme-based strips |
| Commonly missed | Duplicate beta-lactam from clinic plus inpatient MAR; unadjusted IV interval after creatinine rise |
| Ask pharmacy when | CrCl <30 oral or <20 IV, hemodialysis timing, probenecid on MAR, or oral-to-IV switch |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Penicillin allergy / prior beta-lactam reaction | Use caution in penicillin-sensitive patients; cross-reactivity may occur. Stop immediately for anaphylaxis or serious hypersensitivity. |
| Renal impairment / hemodialysis | Extend dosing interval per oral or IV tables; hemodialysis patients need supplemental dosing per labeling. Monitor for seizures if intervals are not adjusted. |
| Older adults | Renal function may be reduced even with “normal” serum creatinine—verify CrCl before repeating high-frequency IV doses |
| Pregnancy | Animal reproduction studies available; adequate human studies lacking—use only if clearly needed per labeling |
| Lactation | Cefuroxime is present in human breast milk per labeling. Weigh infant exposure and clinical need with prescriber. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Stool frequency and character—especially watery, bloody, or foul-smelling diarrhea; obtain stool culture or C. diff testing per protocol when CDAD is suspected
- Allergic symptoms: rash, pruritus, urticaria, respiratory distress, angioedema
- Infection response: temperature trend, localized signs per indication, WBC if ordered
- Renal function and hydration when CrCl is reduced—review basic metabolic panel trends per prescriber
Document
- Allergy verification, dose (mg and mL for suspension), route, time, and patient education on diarrhea and antacid/PPI separation for oral therapy
- Stool character changes, isolation precautions initiated, and prescriber/pharmacy notifications
- Renal dose verification when creatinine clearance changes during therapy
- Completion of antibiotic course or early discontinuation reason (toxicity, culture-directed change)
Patient teaching
- Take the full course even if you feel better—stopping early can cause resistant bacteria
- Report watery or bloody diarrhea, severe stomach pain, or fever right away—these can occur during treatment or weeks afterward
- For oral therapy: take antacids at least 1 hour before or 2 hours after cefuroxime; ask pharmacy how to schedule PPI or H₂ medicines
- Swallow tablets whole—do not crush because of bitter taste; shake liquid medicine well and use only the measuring device provided
- Report rash, itching, swelling of the face or throat, or trouble breathing immediately
- Do not share antibiotics with others
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known beta-lactam or cephalosporin allergy or active serious hypersensitivity (urticaria with systemic symptoms, angioedema, anaphylaxis)
- New watery or bloody diarrhea, abdominal distention, or clinical suspicion of C. difficile—hold and notify before additional doses
- Order does not reflect renal interval adjustment when creatinine clearance requires extended dosing (oral or IV tables)
- Oral axetil scheduled with antacid, PPI, or H₂ blocker at the same time and cannot be rescheduled per labeling
- Duplicate beta-lactam antibiotic on MAR or home med list without prescriber intent
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Cefuroxime spans oral outpatient regimens and IV inpatient therapy, but nurses remain the safety gate for CDAD surveillance, beta-lactam allergy cross-reactivity, renal interval dosing, and oral absorption interactions. Treat every antibiotic course as a stewardship and toxin-monitoring episode—not only an infection-treatment task.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right renal-adjusted interval for oral or IV therapy
- Verify allergy band matches charted beta-lactam history; escalate ambiguous penicillin allergy entries
- Confirm antacid, PPI, and H₂ timing on the MAR for oral axetil; reschedule entries if needed
- Ask about current diarrhea baseline so new symptoms are recognized early
2. High-alert and safety badge
Not a universal high-alert medication, but CDAD and anaphylaxis carry high patient harmApply the same documentation rigor as for high-risk anti-infectives: stool surveillance, allergy escalation, and immediate hold for bloody diarrhea or angioedema.
3. Clinical workflow: hold and question rules
- If diarrhea worsens while on cefuroxime, hold the next dose and notify prescriber—do not assume it is a benign side effect until CDAD is ruled out
- If creatinine rises and IV q8h dosing continues unchanged, contact pharmacy before the next dose
- If a penicillin-allergic patient develops rash after dose one, stop and clarify whether cephalosporin rechallenge is appropriate
4. Critical teach-back questions
- “What diarrhea symptoms should make you call us immediately?” (Patient should name watery or bloody stools, severe cramps, fever—possible C. difficile.)
- “How should you take antacids or stomach medicines with this antibiotic?” (Patient should state at least 1 hour before or 2 hours after oral cefuroxime and ask about PPI timing.)
5. Care coordination
Pharmacist: Renal interval verification for oral and IV routes, antacid/PPI scheduling, probenecid review, and formulation checks for tablet versus suspension
Prescriber / infectious diseases: Notify for suspected CDAD, culture-directed therapy changes, persistent fever, or serious hypersensitivity requiring alternative agents
🧠 Quick mental checklist
- Does this patient have cephalosporin, penicillin, or other beta-lactam allergy documented?
- Is creatinine clearance reduced and does the MAR show the correct oral or IV dosing interval?
- Are antacids, PPIs, or H₂ blockers separated from oral axetil per labeling?
- Any new watery or bloody diarrhea—could this be C. difficile even after therapy ends?
- Is this the correct cefuroxime formulation and route on the MAR (Ceftin oral vs Zinacef IV)?
Cefuroxime NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for cefuroxime using a tabbed inpatient IV case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), stool-trend interpretation, renal-interval documentation cloze, and matrix urgency for CDAD and allergy findings—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Cefuroxime sodium 750 mg IV every 8 hours — 0600 and 1400 given; 2200 due
- 0.9% NaCl 100 mL IV piggyback per institutional protocol
- Omeprazole 20 mg PO daily — given 0700 (patient also on oral axetil at home previously)
- Pharmacy sticker: estimated CrCl 18 mL/min — IV interval adjustment pending; MAR still shows q8h
- Admission: creatinine 1.0 mg/dL; estimated CrCl 52 mL/min; WBC 11.2 ×10⁹/L
- Day 3: creatinine 1.8 mg/dL; estimated CrCl 18 mL/min
- Day 4: WBC 8.4 ×10⁹/L
- Stool C. difficile PCR: not yet collected
- Days 1–2: one soft stool daily; afebrile; HR 82–88
- Day 4 (1400): six liquid stools since midnight; last stool watery with mucus
- Day 4 vitals: T 38.4 °C, HR 118, BP 92/58, RR 22, SpO₂ 96% on room air
- Allergies: penicillin — rash as a child (documented)
- Admitted with community-acquired pneumonia; day 4 of IV cefuroxime
- 1400: abdominal cramping; dizzy when standing; capillary refill 3 s
- Nurse notified pharmacy about rising creatinine yesterday; no new IV interval on MAR
Answer key & rationale
Frequently asked questions
What diarrhea findings suggest C. difficile during cefuroxime therapy?
Labeling warns that Clostridioides difficile-associated diarrhea has been reported with cefuroxime and may range from mild diarrhea to fatal colitis. CDAD must be considered in any patient who develops diarrhea during or after antibacterial use, including more than two months after the last dose. Watery or bloody stools with abdominal cramps and fever warrant urgent evaluation; ongoing antibacterial therapy not directed against C. difficile may need to be discontinued per prescriber and infectious-disease guidance.
When should a nurse hold cefuroxime and contact the prescriber or pharmacist?
Hold for known beta-lactam or cephalosporin hypersensitivity, suspected serious allergic reaction (rash with systemic symptoms, angioedema, anaphylaxis), watery or bloody diarrhea suggesting CDAD, or renal impairment requiring interval adjustment that is not reflected in the order. Also hold if oral axetil cannot be separated from antacids, PPIs, or H₂ blockers per labeling unless pharmacy clarifies timing.
How is cefuroxime dosed in renal impairment?
For oral axetil when creatinine clearance is 10 to less than 30 mL/min, give the standard daily dose every 24 hours; when clearance is below 10 mL/min, give the standard daily dose every 48 hours, with an extra dose after hemodialysis per labeling. For IV sodium when clearance is 10–20 mL/min, 750 mg every 12 hours is typical; below 10 mL/min, 750 mg every 24 hours, with dosing after hemodialysis per labeling.
Why must nurses coordinate antacid, PPI, and H₂ timing with oral cefuroxime?
Cefuroxime axetil absorption is reduced by antacids, H₂-receptor antagonists, and proton-pump inhibitors. Antacids should be taken at least 1 hour before or 2 hours after cefuroxime. PPI and H₂ use should be avoided when possible during oral therapy; coordinate with pharmacy when acid-suppressing medicines are required.
Can patients with penicillin allergy receive cefuroxime?
Cefuroxime is contraindicated in patients with known beta-lactam hypersensitivity. Use caution in penicillin-allergic patients because cross-reactivity among beta-lactams may occur. Stop immediately and escalate for anaphylaxis or serious hypersensitivity; do not rechallenge without prescriber and allergy guidance.
Is cefuroxime safe in pregnancy and breastfeeding?
Animal reproduction studies are available, but adequate and well-controlled studies in pregnant women are lacking—use during pregnancy only if clearly needed per labeling. Cefuroxime is present in human breast milk. Weigh infant exposure and clinical need with the prescriber when breastfeeding.
References
-
U.S. National Library of Medicine. Cefuroxime axetil — Full prescribing information. DailyMed (setid fd79c41e-b0e9-47dc-a3ce-caacdc66bc96).https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd79c41e-b0e9-47dc-a3ce-caacdc66bc96
-
U.S. National Library of Medicine. Cefuroxime sodium — Full prescribing information. DailyMed (setid 19902965-d2d6-433f-982d-0095014df4e8).https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19902965-d2d6-433f-982d-0095014df4e8
-
Centers for Disease Control and Prevention. Clostridioides difficile infection: information for clinicians.https://www.cdc.gov/cdiff/clinicians/diagnosis.html
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.